Search Results - "Montiel, Pilar Martinez"
-
1
Increased risk of thiopurine‐related adverse events in elderly patients with IBD
Published in Alimentary pharmacology & therapeutics (01-10-2019)“…Summary Background Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur in 20%‐30% of cases. Aim To…”
Get full text
Journal Article -
2
Current stage in inflammatory bowel disease: What is next?
Published in World journal of gastroenterology : WJG (28-10-2015)“…In recent years,the incidence of inflammatory bowel disease(IBD) has been on the rise,extending to countries where it was infrequent in the past. As a…”
Get full text
Journal Article -
3
Therapy with stem cells in inflammatory bowel disease
Published in World journal of gastroenterology : WJG (07-02-2014)“…Inflammatory bowel disease(IBD) affects a part of the young population and has a strong impact upon quality of life. The underlying etiology is not known, and…”
Get full text
Journal Article -
4
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn’s patients: Results of the APPRECIA trial
Published in Digestive and liver disease (01-04-2019)“…In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). To…”
Get full text
Journal Article -
5
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Published in Therapeutic advances in gastroenterology (01-11-2021)“…Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week…”
Get full text
Journal Article -
6
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Published in Inflammatory bowel diseases (01-08-2017)“…Golimumab efficacy data in ulcerative colitis (UC) are limited to anti-tumor necrosis factor α (TNF)-naive patients. The aim of this study was to assess the…”
Get full text
Journal Article -
7
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry
Published in Inflammatory bowel diseases (04-03-2020)“…Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze…”
Get full text
Journal Article -
8
Chronic intestinal failure: an overview and future perspectives
Published in Revista española de enfermedades digestivas (01-05-2022)“…Intestinal failure (IF) is the inability of the gut to absorb necessary water, macronutrients, micronutrients, and electrolytes sufficient to sustain life and…”
Get full text
Journal Article -
9
The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU
Published in Inflammatory bowel diseases (22-03-2024)“…Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural…”
Get full text
Journal Article -
10
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Published in Journal of Crohn's and colitis (27-10-2017)“…Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim…”
Get full text
Journal Article -
11
Infliximab-Related Hepatitis: A Case Study and Literature Review
Published in Digestive diseases and sciences (01-11-2013)Get full text
Journal Article -
12
Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury
Published in Revista española de enfermedades digestivas (01-06-2022)“…Pembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical…”
Get full text
Journal Article -
13
Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units
Published in Journal of Crohn's and colitis (01-03-2014)“…While it is commonly accepted that Inflammatory bowel disease (IBD) Comprehensive Care Units (ICCUs) facilitate the delivery of quality care to Crohn's disease…”
Get full text
Journal Article -
14
Safety of propofol sedation directed by endoscopists: how long should we continue to generate evidence?
Published in Revista española de enfermedades digestivas (01-04-2018)“…The administration of propofol by endoscopists is a source of permanent friction with the Societies of Anesthesiology, which is based more on a clear conflict…”
Get full text
Journal Article -
15
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
Published in Journal of Crohn's and colitis (01-06-2012)“…Anti-tumor necrosis factor (TNF)-alpha agents are widely used for the treatment of both inflammatory bowel disease (IBD) and psoriasis. Psoriatic skin lesions…”
Get full text
Journal Article -
16
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Published in Journal of Crohn's and colitis (15-11-2018)“…To assess the likelihood of detecting latent tuberculosis infection [LTBI] by the positive conversion of a serial tuberculin skin test [TST] at 1 year in…”
Get full text
Journal Article -
17
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Published in Journal of clinical medicine (14-01-2022)“…We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term…”
Get full text
Journal Article -
18
Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient
Published in Liver international (01-05-2008)Get full text
Journal Article -
19
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)
Published in Journal of clinical medicine (19-12-2022)“…(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease…”
Get full text
Journal Article -
20
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Published in Journal of Crohn's and colitis (01-07-2017)“…Sensitivity of tuberculin skin test [TST] during screening for latent tuberculosis infection [LTBI] is affected by steroid and/or immunosuppressant therapy…”
Get full text
Journal Article